Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. USO
5. GOOGL
6. APGE
7. MU
8. HOOD
9. DFTX
10. RGNX

Go back to Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma

Array BioPharma (ARRY) PT Raised to $9 at Jefferies; Reiterates Buy

May 11, 2017 8:49 AM EDT

Jefferies raised its price target on Array BioPharma (NASDAQ: ARRY) to $9.00 (from $8.00) while maintaining a Buy rating. Lower 3Q reimbursement revenues of $26M from Novartis resulted in ~11% lower revenue of ~$33M (vs. ~$37M estimates).

For bini/enco in BRAFm CRC, assuming FDA... More